A Warmer, Gentler Way to Find Cancer
The post that landed in my feed this week had a thousand likes and nearly a thousand bookmarks, which is a telling ratio. People weren't just agreeing with it. They were saving it to act on later. The claim was simple and seductive: every year of mammogram screening adds to your breast cancer risk, you can get the very disease you're testing for from the test itself, and so you should skip the X-ray and screen with thermography instead. No radiation. No compression. No cold machine clamping down on the most sensitive tissue you own.
I understand the appeal completely. Mammography is uncomfortable, it generates a lot of false alarms, and the idea of dosing your breast with radiation every year to look for cancer does sound, on its face, like a deal with the devil. Thermography promises to find the problem with nothing but an infrared camera reading the heat coming off your skin. It feels like the gentle, intuitive, body-respecting alternative the medical establishment has been hiding from you.
So let's do what The Corneum does. Let's take the claim apart in two pieces, because it is really two claims wearing one coat. First: does mammography meaningfully cause the cancer it's looking for? Second: can a thermal camera actually find a tumor? The honest answers are "barely" and "no," and the gap between those answers and the confidence of the original post is where this issue lives.
Yes, In the Way You Can Drown Crossing a Bridge
Start with the radiation, because this part isn't pure fiction. X-rays are ionizing radiation, and ionizing radiation can damage DNA, and damaged DNA can, very occasionally, become cancer. The mechanism in the viral post is real. What's missing is any sense of scale.
A standard two-view digital mammogram delivers a mean glandular dose of roughly 2.7 milligray to the breast tissue, a bit higher for 3D tomosynthesis at around 3.7.1 To translate that out of jargon: the radiation from one screening mammogram is in the neighborhood of seven weeks of the natural background radiation you absorb just by existing on this planet, and a small fraction of a single chest CT scan, which runs around 7 millisievert.1 This is not a glowing dose. It is a carefully minimized one.
The best modeling we have puts hard numbers on the trade-off. A 2016 analysis in the Annals of Internal Medicine estimated that screening 100,000 women annually from age 40 to 74 would induce about 125 radiation-caused breast cancers, leading to roughly 16 deaths. Over the same population, that screening would prevent close to 968 breast cancer deaths.2 That is a benefit-to-harm ratio of about 60 to 1. An earlier 2011 paper in Radiology reached a similar place: roughly 497 lives saved against about 11 radiation-induced deaths per 100,000 women, a ratio near 45 to 1.3
The radiation harm is real and the math still favors the test by a wide margin.2,3,4
So is the claim "you can get cancer from the test" technically true? Yes, for a vanishingly small number of women. Is it a reason to skip screening? Only if you'd also refuse to cross a bridge because someone, somewhere, has fallen off one. The premise is real. The magnitude has been inflated roughly sixty-fold, and then handed to you as a reason to do nothing.
One caveat I owe you, because it cuts the other way: these radiation-risk figures are modeling estimates, extrapolated downward from atomic-bomb survivor data using the linear-no-threshold assumption. That assumption almost certainly overstates the harm at doses this low. In other words, the real radiation risk from a mammogram is probably even smaller than the 60-to-1 math suggests, not larger.
The premise is real. The magnitude has been inflated roughly sixty-fold, and then handed to you as a reason to do nothing.
On the "cancer from the test" claimHeat Is Not a Tumor
Now the second claim, which is the one that actually matters. Thermography, sometimes sold as "digital infrared thermal imaging" or "no-touch breast scanning," uses an infrared camera to map the temperature of the skin over the breast. The theory is that a growing tumor recruits new blood vessels and runs a faster metabolism, and that this extra heat shows up as a hot spot on the surface.
The theory isn't crazy. Angiogenesis and elevated metabolism are real features of many tumors. The problem is everything between the tumor and the camera. A thermal sensor reads the surface of your skin, not the tissue centimeters beneath it. Heat diffuses, spreads sideways, and gets buffered by fat, so a small deep tumor produces little or no surface signal. Meanwhile, perfectly innocent things raise skin temperature: inflammation, dense tissue, hormonal cycling, a warm room, exercise, even a recent cup of coffee. The camera can't tell a benign hot spot from a malignant one because it isn't measuring cancer. It's measuring warmth, and inferring the rest.
Contrast that with what a mammogram does. It produces an actual image of the internal structure of the breast, including microcalcifications, the tiny mineral specks that are often the very first visible sign of an early, still-curable cancer, frequently years before anything is warm enough or large enough to feel. Thermography cannot see a microcalcification. It was never designed to. These two tools are not competing at the same task. One looks for the cancer. The other looks for a temperature.
The camera can't tell a benign hot spot from a malignant one because it isn't measuring cancer. It's measuring warmth, and inferring the rest.
On the mechanism of thermographyWhat the Studies Found When They Pointed the Camera at Real Breasts
A clever mechanism means nothing until you test it on actual patients, so let's look at what happened when researchers did.
Design. A systematic review pooling the published evidence on thermography as a breast cancer screening and diagnostic tool.4
Results: As a screening test, thermography showed a median sensitivity of about 47% — meaning it missed close to half of the cancers that were actually present — with a false-positive rate near 31%. Sensitivity across studies ranged from 25% to 70%.
Limitation: Older and heterogeneous studies, but the direction is consistent across decades: as a standalone screen, the test misses too much to be safe.
Design. A 2024 meta-analysis of 22 studies reporting pooled diagnostic accuracy, the most favorable recent dataset thermography's defenders point to.5
Results: Pooled sensitivity of 88.5% and specificity of 71.8% — numbers that sound respectable until you read the fine print.
Limitation: Extreme statistical heterogeneity, with an I-squared near 99%, small and selected samples, often symptomatic women rather than a screening population, and no standardized protocol. The authors themselves conclude the evidence does not support thermography as an alternative or even an adjunct. Pooled numbers this heterogeneous don't generalize to a healthy woman walking in for a routine screen.
Design. The landmark U.S. screening program of the 1970s enrolled roughly 280,000 women and initially included thermography alongside mammography and physical exam.6
Results: Thermography performed so poorly on sensitivity and specificity that it was dropped from the program in 1977. It has never recovered scientific credibility as a screening tool since.
Limitation: 1970s-era equipment, and proponents argue modern cameras and AI are better. Forty-five years later, the high-quality screening data to prove that still does not exist.
That is the entire arc of the evidence in three cards. The mechanism is plausible, the historical trial threw it out, the modern systematic review found it misses half of cancers, and the single most flattering recent meta-analysis is so internally inconsistent that its own authors won't endorse the test. The American Cancer Society's position is blunt: no study has shown thermography to be an effective tool for detecting breast cancer.7
A Regulator That Almost Never Says This, Saying It Five Times
Regulators are usually careful and hedged. So it's worth noticing how undiplomatic the FDA has been here. The agency has cleared thermography devices only as an adjunct to a primary diagnostic test, never as a standalone screen, since 1982.8 Then in February 2019 it went further than clearance status and issued a direct consumer safety communication with a title that needs no interpretation: Breast Cancer Screening: Thermogram No Substitute for Mammogram.8
In that communication the FDA stated plainly that there is no valid scientific evidence that thermography is effective when used alone, and that relying on it instead of mammography may cause patients to miss the chance to detect cancer at its earliest, most treatable stage.8 The same week, the agency sent warning letters to clinics, including one to a California provider, for illegally marketing thermography as a sole screening method for breast cancer.9 Five letters in total.
Why does a federal agency bother writing five letters about an infrared camera? Follow the money. Thermography is almost never covered by insurance. It's a cash-pay service, typically running 150 to 500 dollars a scan, and it's frequently sold direct-to-consumer by wellness, chiropractic, and naturopathic practices.9 The financial incentive to market a 300-dollar scan as a complete mammogram replacement is enormous, and the FDA's letters were aimed at exactly that behavior. The regulatory record here isn't ambiguous. It's a paper trail.
Missed cancers
A standalone test that misses roughly half of breast cancers can return "normal" to a woman who has one. The cost of a false negative here is measured in stage and survival.
False reassurance
A clean thermogram can talk a woman out of the mammogram that would have caught her tumor early, converting a curable cancer into a late diagnosis.
Cash-pay incentive
Not covered by insurance, sold for $150–$500 by wellness clinics. The seller has a direct financial stake in calling it a mammogram replacement.
No microcalcifications
The earliest signs of many breast cancers are tiny mineral deposits that only an imaging test can see. A heat map is physically incapable of detecting them.
Mammography Earned Some of This Distrust
Here's where I part ways with the reflexive defenders of screening. The viral post is wrong about thermography, but the anger underneath it isn't baseless. Mammography has real, well-documented harms, and pretending otherwise is how you lose people to the infrared camera in the first place.
The false positives are not rare. Over ten years of annual screening, somewhere around 50 to 60% of women will be called back at least once for something that turns out to be nothing, and a meaningful fraction, roughly 7 to 12%, will undergo a biopsy that comes back benign.10 That is a decade of intermittent fear and needles for findings that were never going to hurt anyone. Switching to every-other-year screening cuts that false-positive burden roughly in half.
Then there's overdiagnosis, the subtler and more troubling harm. The 2012 Independent UK Panel, led by epidemiologist Michael Marmot, estimated that about 19% of cancers detected through screening are overdiagnosed: real cancers by the pathology, but ones that would never have grown enough to threaten the woman's life, yet still get treated with surgery, radiation, or chemotherapy.11 The same panel estimated mammography reduces breast cancer mortality by about 20%, and the U.S. Preventive Services Task Force in 2024 graded the benefit as "moderate," now recommending biennial screening starting at age 40.12 The Cochrane reviewers have argued the mortality benefit is smaller and the overdiagnosis harm larger. That debate is legitimate, and it is ongoing among serious people.
Design. A panel commissioned to adjudicate the contested evidence on mammography's benefits and harms.11
Results: Roughly a 20% relative reduction in breast cancer mortality, set against an estimated ~19% overdiagnosis rate among screen-detected cancers.
Limitation: Overdiagnosis estimates vary widely by method; Cochrane's reviewers put the harm higher and the benefit lower. The honest summary is "real benefit, real harm, genuine debate."
So mammography is not above criticism. It over-recalls, it sometimes finds cancers that didn't need finding, and its absolute mortality benefit for any one woman is modest. All of that is true and worth discussing with your physician. None of it makes thermography a solution. The legitimate complaints about an imperfect-but-proven test do not transfer into an endorsement of an unproven one. You don't fix a test that recalls too often by switching to a test that misses half the cancers entirely.
The Verdict
The viral claim fails on both of its halves. The "you can get cancer from the test" premise is real in mechanism but exaggerated by roughly sixty-fold against the benefit, and the very modeling that produces that figure probably overstates the radiation risk to begin with. The proposed alternative has no valid evidence as a standalone screen. It missed too many cancers to survive the BCDDP in the 1970s, it shows a median sensitivity around 47% in systematic review, and the most flattering modern meta-analysis is so heterogeneous that its own authors decline to endorse the test. The FDA has cleared it only as an adjunct for four decades and has issued direct warnings against its use as a substitute.
This is what "Marketing Hype" means in our rating system: the claims dramatically exceed the evidence, and a real product is being sold on the strength of that gap. Thermography packages legitimate grievances — discomfort, false positives, the word "radiation" — into a cash-pay scan that cannot do the job it's being sold to do. That's not a gentler mammogram. It's a different machine measuring a different thing, dressed in the language of empowerment.
The honest move isn't to defend mammography as flawless. It's to take its real flaws to your doctor, talk about screening intervals and your personal risk, and not trade a proven test for an infrared camera because a discomfort you understand got reframed as a danger you don't.
A test that misses half of cancers isn't a gentler mammogram. It's a coin flip with a marketing budget.
Dr. Maren ColeMammography's radiation saves roughly sixty lives for every one it might cost, and thermography misses about half the cancers it claims to find. The discomfort is real; the alternative isn't.
- 1. Mean glandular dose and dose comparison data for 2D and 3D mammography. Mammography radiation dose summaries; mean glandular dose ≈2.7 mGy (2D), ≈3.7 mGy (tomosynthesis); background ≈3.1 mSv/yr; chest CT ≈7 mSv. 2023.
- 2. Miglioretti DL, et al. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening. Annals of Internal Medicine. 2016;164(4):205–214. ~125 induced cancers and ~16 deaths vs. ~968 deaths averted per 100,000 women screened annually age 40–74.
- 3. Yaffe MJ, Mainprize JG. Risk of Radiation-Induced Breast Cancer From Mammographic Screening. Radiology. 2011;258(1):98–105. ~497 lives saved vs. ~11 radiation-induced deaths per 100,000; benefit:risk ≈45:1.
- 4. Kennedy DA, Lee T, Seely D. A Comparative Review of Thermography as a Breast Cancer Screening Technique. Integrative Cancer Therapies. 2009;8(1):9–16. Median screening sensitivity ~47% (range 25–70%); false-positive rate ~31%.
- 5. Systematic review and meta-analysis of breast thermography diagnostic accuracy (22 studies). Systematic Reviews. 2024. Pooled sensitivity 88.5%, specificity 71.8%, with I²≈99%; authors conclude evidence does not support thermography as alternative or adjunct.
- 6. Cunningham M, et al. The Breast Cancer Detection Demonstration Project (1973–1981). CA: A Cancer Journal for Clinicians. 1997;47(3):131. ~280,000 women; thermography included then discontinued in 1977 for poor sensitivity/specificity.
- 7. American Cancer Society / breastcancer.org. Thermography for breast cancer screening. No study has shown thermography to be effective for detecting breast cancer. 2024.
- 8. U.S. Food and Drug Administration. Breast Cancer Screening: Thermogram No Substitute for Mammogram. FDA Safety Communication / Consumer Update. Feb 25, 2019. No valid scientific evidence thermography is effective alone or as an adjunct; cleared as adjunct only since 1982.
- 9. U.S. Food and Drug Administration. FDA Issues Warning Letter to Clinic Illegally Marketing Unapproved Thermography Device. FDA Press Announcement and Warning Letters (incl. Total Thermal Imaging Inc., 02/22/2019). 2019.
- 10. Ho TQH, et al. (Breast Cancer Surveillance Consortium). Cumulative Probability of False-Positive Results After 10 Years of Screening. JAMA Network Open. 2022. ~50–60% cumulative false-positive recall over 10 years of annual screening; biennial roughly halves it.
- 11. Marmot MG, et al. The Benefits and Harms of Breast Cancer Screening: The Independent UK Panel on Breast Cancer Screening. The Lancet. 2012;380(9855):1778–1786. ~20% relative mortality reduction; ~19% overdiagnosis among screen-detected cancers.
- 12. U.S. Preventive Services Task Force. Breast Cancer: Screening — Final Recommendation. USPSTF. 2024. Biennial mammography age 40–74, Grade B, "moderate" net benefit.
- 13. Why Do Radiologists Disown Breast Thermography? Cancers (MDPI). 2025. Reviews the BCDDP legacy and the Society of Breast Imaging position declining to support thermography as screen or adjunct.